Impact Biomedical (IBO) Receivables - Other (2023)

Impact Biomedical (IBO) posted Receivables - Other of $128000.0 for Q4 2023, up 36.17% on a QoQ basis from $94000.0 in Q2 2023.

Impact Biomedical (IBO) Receivables - Other (2023) Analysis & Trends

Impact Biomedical's Receivables - Other history runs 1 years deep, the most recent figure standing at $128000.0 for Q4 2023.

Quarterly Receivables - Other changed N/A year-over-year to $128000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $128000.0 (changed N/A YoY) and the FY2024 annual result came in at -$128000.0, down 200.0% from the prior year.
Receivables - Other was $128000.0 for Q4 2023 at Impact Biomedical, up from $94000.0 in the prior quarter.
Across five years, Receivables - Other topped out at $128000.0 in Q4 2023 and bottomed at $94000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Impact Biomedical	47.44 Mn	50.67 Mn	-

Download Data